Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

INTRODUCTION: The phase 3 APOLLO study demonstrated significantly better progression-free survival (PFS) and clinical responses with daratumumab, pomalidomide, and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM). On the bas...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jianming, Berringer, Heather, Heeg, Bart, Ruan, Haoyao, Kampfenkel, Tobias, Dwarakanathan, Harikumaran R., Johnston, Stephen, Mendes, João, Lam, Annette, Bathija, Sacheeta, Mackay, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402768/
https://www.ncbi.nlm.nih.gov/pubmed/35876974
http://dx.doi.org/10.1007/s12325-022-02226-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402768/
https://www.ncbi.nlm.nih.gov/pubmed/35876974
http://dx.doi.org/10.1007/s12325-022-02226-x

Ejemplares similares